Literature DB >> 18639865

AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli.

Vaishnav Krishnan1, Ming-Hu Han, Michelle Mazei-Robison, Sergio D Iñiguez, Jessica L Ables, Vincent Vialou, Olivier Berton, Subroto Ghose, Herbert E Covington, Matthew D Wiley, Ross P Henderson, Rachael L Neve, Amelia J Eisch, Carol A Tamminga, Scott J Russo, Carlos A Bolaños, Eric J Nestler.   

Abstract

BACKGROUND: The neurobiological mechanisms by which only a minority of stress-exposed individuals develop psychiatric diseases remain largely unknown. Recent evidence suggests that dopaminergic neurons of the ventral tegmental area (VTA) play a key role in the manifestation of stress vulnerability.
METHODS: Using a social defeat paradigm, we segregated susceptible mice (socially avoidant) from unsusceptible mice (socially interactive) and examined VTA punches for changes in neurotrophic signaling. Employing a series of viral vectors, we sought to causally implicate these neurotrophic changes in the development of avoidance behavior.
RESULTS: Susceptibility to social defeat was associated with a significant reduction in levels of active/phosphorylated AKT (thymoma viral proto-oncogene) within the VTA, whereas chronic antidepressant treatment (in mice and humans) increased active AKT levels. This defeat-induced reduction in AKT activation in susceptible mice was both necessary and sufficient to recapitulate depressive behaviors associated with susceptibility. Pharmacologic reductions in AKT activity also significantly raised the firing frequency of VTA dopamine neurons, an important electrophysiologic hallmark of the susceptible phenotype.
CONCLUSIONS: These studies highlight a crucial role for decreases in VTA AKT signaling as a key mediator of the maladaptive cellular and behavioral response to chronic stress.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639865      PMCID: PMC2742561          DOI: 10.1016/j.biopsych.2008.06.003

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  50 in total

Review 1.  Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress.

Authors:  Dennis S Charney
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

Review 2.  Dopamine, learning and motivation.

Authors:  Roy A Wise
Journal:  Nat Rev Neurosci       Date:  2004-06       Impact factor: 34.870

Review 3.  Role of stress in the pathogenesis of the metabolic syndrome.

Authors:  Roland Rosmond
Journal:  Psychoneuroendocrinology       Date:  2005-01       Impact factor: 4.905

Review 4.  Neurotrophic mechanisms in drug addiction.

Authors:  Carlos A Bolaños; Eric J Nestler
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

5.  Pharmacological validation of the chronic mild stress model of depression.

Authors:  M Papp; E Moryl; P Willner
Journal:  Eur J Pharmacol       Date:  1996-01-25       Impact factor: 4.432

6.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.

Authors:  T F Franke; S I Yang; T O Chan; K Datta; A Kazlauskas; D K Morrison; D R Kaplan; P N Tsichlis
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

7.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

Authors:  C J Vlahos; W F Matter; K Y Hui; R F Brown
Journal:  J Biol Chem       Date:  1994-02-18       Impact factor: 5.157

8.  Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli.

Authors:  Mark A Ungless; Peter J Magill; J Paul Bolam
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

Review 9.  Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention.

Authors:  Dennis S Charney; Husseini K Manji
Journal:  Sci STKE       Date:  2004-03-16

10.  Posttraumatic stress disorder in the National Comorbidity Survey.

Authors:  R C Kessler; A Sonnega; E Bromet; M Hughes; C B Nelson
Journal:  Arch Gen Psychiatry       Date:  1995-12
View more
  87 in total

Review 1.  Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Frank M Dautzenberg; James B Lohr; Sandra Braun; Robert H Oakley
Journal:  Neuropharmacology       Date:  2011-11-25       Impact factor: 5.250

Review 2.  Animal models of stress vulnerability and resilience in translational research.

Authors:  Sebastian H Scharf; Mathias V Schmidt
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

Review 3.  Virogenetic and optogenetic mechanisms to define potential therapeutic targets in psychiatric disorders.

Authors:  Ming-Hu Han; Allyson K Friedman
Journal:  Neuropharmacology       Date:  2011-09-17       Impact factor: 5.250

Review 4.  Linking molecules to mood: new insight into the biology of depression.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Am J Psychiatry       Date:  2010-09-15       Impact factor: 18.112

5.  Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis.

Authors:  Sabrina D Robertson; Heinrich J G Matthies; W Anthony Owens; Vidiya Sathananthan; Nicole S Bibus Christianson; J Phillip Kennedy; Craig W Lindsley; Lynette C Daws; Aurelio Galli
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 6.  The molecular and cellular mechanisms of depression: a focus on reward circuitry.

Authors:  Megan E Fox; Mary Kay Lobo
Journal:  Mol Psychiatry       Date:  2019-04-09       Impact factor: 15.992

7.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

9.  Fluoxetine exposure during adolescence alters responses to aversive stimuli in adulthood.

Authors:  Sergio D Iñiguez; Lyonna F Alcantara; Brandon L Warren; Lace M Riggs; Eric M Parise; Vincent Vialou; Katherine N Wright; Genesis Dayrit; Steven J Nieto; Matthew B Wilkinson; Mary K Lobo; Rachael L Neve; Eric J Nestler; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

Review 10.  HCN Channel Targets for Novel Antidepressant Treatment.

Authors:  Stacy M Ku; Ming-Hu Han
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.